LT3801536T - Sepiapterino vartojimas nevalgius, skirtas panaudoti taikant sepiapterino koncentracijos plazmoje padidinimo būdą - Google Patents
Sepiapterino vartojimas nevalgius, skirtas panaudoti taikant sepiapterino koncentracijos plazmoje padidinimo būdąInfo
- Publication number
- LT3801536T LT3801536T LTEPPCT/US2019/034523T LTUS2019034523T LT3801536T LT 3801536 T LT3801536 T LT 3801536T LT US2019034523 T LTUS2019034523 T LT US2019034523T LT 3801536 T LT3801536 T LT 3801536T
- Authority
- LT
- Lithuania
- Prior art keywords
- sepiapterin
- administration
- food
- increasing
- plasma exposure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862677943P | 2018-05-30 | 2018-05-30 | |
US201862771398P | 2018-11-26 | 2018-11-26 | |
US201962822376P | 2019-03-22 | 2019-03-22 | |
GC201937663 | 2019-05-28 | ||
PCT/US2019/034523 WO2019232130A1 (en) | 2018-05-30 | 2019-05-30 | Methods for increasing sepiapterin plasma exposure |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3801536T true LT3801536T (lt) | 2024-09-25 |
Family
ID=68699037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/US2019/034523T LT3801536T (lt) | 2018-05-30 | 2019-05-30 | Sepiapterino vartojimas nevalgius, skirtas panaudoti taikant sepiapterino koncentracijos plazmoje padidinimo būdą |
Country Status (20)
Country | Link |
---|---|
US (2) | US11617752B2 (lt) |
EP (2) | EP3801536B1 (lt) |
JP (2) | JP7502197B2 (lt) |
CN (1) | CN112703002A (lt) |
AU (2) | AU2019277382B2 (lt) |
CA (1) | CA3102106A1 (lt) |
DK (1) | DK3801536T3 (lt) |
ES (1) | ES2986920T3 (lt) |
FI (1) | FI3801536T3 (lt) |
HR (1) | HRP20241213T1 (lt) |
HU (1) | HUE068589T2 (lt) |
LT (1) | LT3801536T (lt) |
MD (1) | MD3801536T2 (lt) |
MX (2) | MX2020012979A (lt) |
PL (1) | PL3801536T3 (lt) |
PT (1) | PT3801536T (lt) |
RS (1) | RS65874B1 (lt) |
SI (1) | SI3801536T1 (lt) |
SM (1) | SMT202400430T1 (lt) |
WO (1) | WO2019232130A1 (lt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
WO2019046849A1 (en) | 2017-09-01 | 2019-03-07 | Censa Pharmaceuticals Inc. | PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF |
MX2020012980A (es) * | 2018-05-30 | 2021-04-29 | Ptc Therapeutics Mp Inc | Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina. |
EP4093405A1 (en) * | 2020-01-24 | 2022-11-30 | PTC Therapeutics MP, Inc. | Methods for treating parkinson's disease with sepiapterin |
US20240122931A1 (en) * | 2021-02-09 | 2024-04-18 | Ptc Therapeutics Mp, Inc. | Methods for treating covid-19 with sepiapterin |
CA3207811A1 (en) * | 2021-02-09 | 2022-08-18 | Christopher RABENDER | Methods for treating glioblastomas with sepiapterin |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
EP0854934A4 (en) | 1995-08-18 | 2000-09-06 | Donald W Landry | DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS |
US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
EP1696877A4 (en) * | 2003-11-13 | 2010-06-09 | Gen Hospital Corp | PROCESS FOR PAIN TREATMENT |
MXPA06005451A (es) | 2003-11-17 | 2007-01-26 | Biomarin Pharm Inc | Metodos y composiciones para el tratamiento de trastornos metabolicos. |
ES2755334T3 (es) | 2003-11-17 | 2020-04-22 | Merck & Cie | Proceso para la preparación de formas cristalinas B de clorhidrato de (6R)-L-eritro-tetrahidrobiopterina a partir de otras formas cristalinas |
AU2004290692A1 (en) | 2003-11-17 | 2005-06-02 | Biomarin Pharmaceutical Inc. | Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin |
MX2007005039A (es) | 2004-11-17 | 2007-06-19 | Biomarin Pharm Inc | Formulacion de tableta estable. |
JP2008523090A (ja) | 2004-12-08 | 2008-07-03 | バイオマリン ファーマシューティカル インコーポレイテッド | 新生児肺高血圧症の治療のための方法および組成物 |
DE602006005349D1 (de) | 2005-04-28 | 2009-04-09 | Shiratori Pharm | Verfahren zur herstellung von hydrazon-derivaten |
US20080075666A1 (en) | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
CN101678025A (zh) | 2007-04-11 | 2010-03-24 | 生物马林药物股份有限公司 | 四氢生物蝶呤组合物及其测量方法 |
JP2011530540A (ja) | 2008-08-12 | 2011-12-22 | オルファ スイス ゲーエムベーハー | テトラヒドロビオプテリンを含有する医薬剤形 |
EP2562176B1 (en) | 2010-04-22 | 2018-08-15 | Nihon University | Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
CN103458900A (zh) | 2011-03-01 | 2013-12-18 | 鲁必康研究私人有限公司 | 四氢生物蝶呤的稳定组合物 |
US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
US9181254B2 (en) | 2012-05-07 | 2015-11-10 | Shiratori Pharmaceutical Co., Ltd. | Method for producing sepiapterin and tetrahydrolactoylpterin |
US10365267B2 (en) | 2014-10-31 | 2019-07-30 | Children's Medical Center Corporation | Methods and assays relating to sepiapterin reductase inhibition |
MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
MA46973A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Polymorphes de sépiaptérine et leurs sels |
WO2019046849A1 (en) * | 2017-09-01 | 2019-03-07 | Censa Pharmaceuticals Inc. | PHARMACEUTICAL COMPOSITION COMPRISING SEPAPTERINE AND USES THEREOF |
KR102642601B1 (ko) * | 2017-11-23 | 2024-03-05 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 표시 장치 및 전자 기기 |
MX2020012980A (es) | 2018-05-30 | 2021-04-29 | Ptc Therapeutics Mp Inc | Composiciones y métodos para incrementar la exposición plasmática de tetrahidrobiopterina. |
MX2020012978A (es) | 2018-05-30 | 2021-04-28 | Ptc Therapeutics Mp Inc | Sales de sepiapterina farmacéuticamente aceptables. |
PT4009978T (pt) | 2019-08-05 | 2024-11-05 | Univ Virginia Commonwealth | Utiilização de sepiapterina e metabolitos da mesma para tratar a exposição à radiação |
JP2022549834A (ja) | 2019-09-25 | 2022-11-29 | ピーティーシー セラピューティクス エムピー,インコーポレイテッド | 高フェニルアラニン血症の治療方法 |
-
2019
- 2019-05-30 AU AU2019277382A patent/AU2019277382B2/en active Active
- 2019-05-30 HU HUE19811888A patent/HUE068589T2/hu unknown
- 2019-05-30 HR HRP20241213TT patent/HRP20241213T1/hr unknown
- 2019-05-30 CN CN201980050839.7A patent/CN112703002A/zh active Pending
- 2019-05-30 MX MX2020012979A patent/MX2020012979A/es unknown
- 2019-05-30 ES ES19811888T patent/ES2986920T3/es active Active
- 2019-05-30 EP EP19811888.7A patent/EP3801536B1/en active Active
- 2019-05-30 PT PT198118887T patent/PT3801536T/pt unknown
- 2019-05-30 PL PL19811888.7T patent/PL3801536T3/pl unknown
- 2019-05-30 WO PCT/US2019/034523 patent/WO2019232130A1/en active Application Filing
- 2019-05-30 LT LTEPPCT/US2019/034523T patent/LT3801536T/lt unknown
- 2019-05-30 FI FIEP19811888.7T patent/FI3801536T3/fi active
- 2019-05-30 CA CA3102106A patent/CA3102106A1/en active Pending
- 2019-05-30 SM SM20240430T patent/SMT202400430T1/it unknown
- 2019-05-30 RS RS20240943A patent/RS65874B1/sr unknown
- 2019-05-30 DK DK19811888.7T patent/DK3801536T3/da active
- 2019-05-30 US US17/059,719 patent/US11617752B2/en active Active
- 2019-05-30 MD MDE20210340T patent/MD3801536T2/ro unknown
- 2019-05-30 JP JP2020566655A patent/JP7502197B2/ja active Active
- 2019-05-30 SI SI201930841T patent/SI3801536T1/sl unknown
- 2019-05-30 EP EP24187175.5A patent/EP4454704A3/en active Pending
-
2020
- 2020-11-30 MX MX2024005935A patent/MX2024005935A/es unknown
-
2023
- 2023-03-31 US US18/129,177 patent/US20230381181A1/en active Pending
-
2024
- 2024-02-05 JP JP2024015822A patent/JP2024069192A/ja active Pending
-
2025
- 2025-02-06 AU AU2025200814A patent/AU2025200814A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210220363A1 (en) | 2021-07-22 |
AU2019277382A1 (en) | 2021-01-21 |
PT3801536T (pt) | 2024-09-19 |
MX2020012979A (es) | 2021-04-29 |
ES2986920T3 (es) | 2024-11-13 |
AU2019277382B2 (en) | 2025-01-09 |
FI3801536T3 (fi) | 2024-08-29 |
HUE068589T2 (hu) | 2025-01-28 |
HRP20241213T1 (hr) | 2024-11-22 |
MD3801536T2 (ro) | 2024-11-30 |
AU2025200814A1 (en) | 2025-02-27 |
CN112703002A (zh) | 2021-04-23 |
EP3801536A4 (en) | 2022-03-23 |
WO2019232130A1 (en) | 2019-12-05 |
DK3801536T3 (da) | 2024-08-19 |
SMT202400430T1 (it) | 2024-11-15 |
JP2021525729A (ja) | 2021-09-27 |
JP7502197B2 (ja) | 2024-06-18 |
JP2024069192A (ja) | 2024-05-21 |
US11617752B2 (en) | 2023-04-04 |
US20230381181A1 (en) | 2023-11-30 |
EP4454704A2 (en) | 2024-10-30 |
SI3801536T1 (sl) | 2024-12-31 |
EP3801536B1 (en) | 2024-07-17 |
EP4454704A3 (en) | 2025-01-01 |
RS65874B1 (sr) | 2024-09-30 |
EP3801536A1 (en) | 2021-04-14 |
PL3801536T3 (pl) | 2025-02-03 |
CA3102106A1 (en) | 2019-12-05 |
MX2024005935A (es) | 2024-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SMT202400430T1 (it) | Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina | |
IL279632A (en) | Compounds and Methods for Reducing LRRK2 Expression | |
IL284877B (en) | Plasma-based coatings and methods for their preparation and use | |
HRP20211272T8 (hr) | 24-hidroksisteroli supstituirani na poziciji 11 za uporabu u liječenju stanja povezanih sa nmda | |
PL3043749T3 (pl) | System i sposób podawania implantu do anuloplastyki | |
IL279101A (en) | Salts of spiafatrin are accepted in pharmacies | |
EP3272254A4 (en) | Plasma non-stick pan and method for manufacturing same | |
PT3286166T (pt) | Inibidores de replicação do vírus da imunodeficiência humana | |
HK1247143A1 (zh) | 用於製備並施用血液組分的儀器和方法 | |
EP3522795A4 (en) | METHOD AND DEVICE FOR STENT INSERTION | |
EP3333629A4 (en) | IMAGING AND FORMING PROCEDURES USING PROJECTION OPERATION AND BACK PROJECTION METHOD | |
EP3096763A4 (en) | Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | |
GB201516802D0 (en) | Apparatus and method for determination of the dose of a powder inhalation formulation | |
EP2904905B8 (en) | An apparatus for aligning and positioning pieces of food dough | |
HK1219424A1 (zh) | 含有他達拉非的口腔崩解型膜製劑及其製備方法 | |
SG11201709707TA (en) | Method for reducing the defectivity of a block copolymer film | |
GB2532606B (en) | Multiple camera apparatus and method for synchronized autofocus | |
EP3360531A4 (en) | KIT PREPARATION AND DOSE SETTING METHOD | |
IL275486A (en) | Formulation of a layer containing vardenafil, method for its preparation and use | |
EP3198745A4 (en) | Method and network node for facilitating timing synchronization in network | |
HUP1400104A2 (en) | Compositions comprising indometacine, its pharmaceutically acceptable salts and cocrystals; and process for the preparation | |
GB201417597D0 (en) | Film dispenser and method for manufacture thereof | |
HK1212953A1 (zh) | 多層膜減反射玻璃及其製備方法 | |
ZA202008062B (en) | Pharmaceutically acceptable salts of sepiapterin | |
HUP1800397A2 (en) | Process for the preparation of lumateperone and salts thereof |